4. Spallarossa P, Altieri P, Aloi C, Garibaldi S, Barisione C, et al. (2009) Doxorubicin induces senescence or apoptosis in rat neonatal cardiomyocytes by regulating the expression levels of the telomere binding factors 1 and 2. Am J Physiol Heart Circ Physiol 297: H2169–H2181. 5. Hayflick L, Moorhead PS (1961)The serial cultivation of human diploid cell strains. Exp Cell Res 25: 585–621. 6. Lin AW, Barradas M, Stone JC, van Aelst L, Serrano M, et al. (1998) Premature senescence involving p53 and p16 is activated in response to constitutive MEK/ MAPK mitogenic signaling. Genes Dev 12: 3008–3019. 7. Vigneron A, Roninson IB, Gamelin E, Coqueret O (2005) Src inhibits adriamycin-induced senescence and G2 checkpoint arrest by blocking the induction of p21waf1. Cancer Res 65: 8927–8935. 8. Spallarossa P, Altieri P, Barisione C, Passalacqua M, Aloi C, et al. (2010) p38 MAPK and JNK antagonistically control senescence and cytoplasmic p16INK4A expression in doxorubicin-treated endothelial progenitor cells. PLoS One 5: e15583. 9. Spallarossa P, Altieri P, Garibaldi S, Ghigliotti G, Barisione C, et al. (2006) Matrix metalloproteinase-2 and -9 are induced differently by doxorubicin in H9c2 cells: The role of MAP kinases and NAD(P)H oxidase. Cardiovasc Res 69: 736–745. 10. Berger J, Moller DE (2002) The mechanisms of action of PPARs Annu. Rev. Med. 53,409–435. 11. Karpe F, Ehrenborg EE (2009) PPARdelta in humans: genetic and pharmacological evidence for a significant metabolic function. Curr Opin Lipidol 20: 333–336. 12. Wang YX, Lee CH, Tiep S, Yu RT, Ham J, et al. (2003) Peroxisome- proliferator-activated receptor d activates fat metabolism to prevent obesity. Cell 113: 159–170. 13. Di Paola R, Esposito E, Mazzon E, Paterniti I, Galuppo M, et al. (2010) GW0742,a selective PPAR-beta/delta agonist, contributes to the resolution of inflammation after gut ischemia/reperfusion injury. J Leukoc Biol 88: 291–301. 14. Ding G, Cheng L, Qin Q, Frontin S, Yang Q (2006) PPARd modulates lipopolysaccharide-induced TNFa inflammation signaling in cultured cardio- myocytes J Mol Cell Cardiol 40: 821–828. 15. Fan Y, Wang Y, Tang Z, Zhang H, Qin X, et al. (2008) Suppression of pro- inflammatory adhesion molecules by PPAR-d in human vascular endothelial cells Arterioscler Thromb Vasc Biol 28: 315–321. 16. Lee CH, Chawla A, Urbiztondo N, Liao D, Boisvert WA, et al. (2003) Transcriptional repression of atherogenic inflammation: modulation by PPARdelta. Science 302: 453–457. 17. Takata Y, Liu J, Yin F, Collins AR, Lyon CJ, et al. (2008) PPARdelta-mediated antiinflammatory mechanisms inhibit angiotensin II-accelerated atherosclerosis. Proc Natl Acad Sci U S A 105: 4277–4282. 18. Yu RY, Wang X, Pixley FJ, Yu JJ, Dent AL, et al. (2005) BCL-6 negatively regulates macrophage proliferation by suppressing autocrine IL-6 production. Blood 105: 1777–17784. 19. Glauser DA, Schlegel W (2009) The FoxO/Bcl-6/cyclin D2 pathway mediates metabolic and growth factor stimulation of proliferation in Min6 pancreatic beta-cells. J Recept Signal Transduct Res 29: 293–308. 20. Dent AL, Vasanwala FH, Toney LM (2002) Regulation of gene expression by the proto-oncogene BCL-6. Crit Rev Oncol Hematol 41: 1–9. 21. Brown JD, Plutzky J (2007) Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets. Circulation 115: 518–33. 22. van Bilsen M, van Nieuwenhoven FA(2010) PPARs as therapeutic targets in cardiovascular disease. Expert Opin Ther Targets. 14: 1029–45. 23. Shvarts A, Brummelkamp TR, Scheeren F, Koh E, Daley GQ, et al. (2002) A senescence rescue screen identifies BCL6 as an inhibitor of anti-proliferative p19ARF–p53 signaling Genes Dev 16: 681–816. 24. Kim HJ, Ham SA, Paek KS, Hwang JS, Jung SY, et al. (2011) Transcriptional up-regulation of antioxidant genes by PPARd inhibits angiotensin II-induced premature senescence in vascular smooth muscle cells. Biochem Biophys Res Commun 406: 564–569. 25. Karlseder J, Smogorzewska A, de Lange T (2002) Senescence induced by altered telomere state, not telomere loss. Science 295: 2446–2449. 26. Pesant M, Sueur S, Dutartre P, Tallandier M, Grimaldi PA, et al. (2006) Peroxisome proliferator-activated receptor delta (PPARdelta) activation protects H9c2 cardiomyoblasts from oxidative stress-induced apoptosis. Cardiovasc Res 69: 440–449. 27. Plutzky J (2003) PPARs as therapeutic targets: reverse cardiology? Science 302: 406–407. 28. Kharroubi I, Lee CH, Hekerman P, Darville MI, Evans RM, et al. (2006) BCL- 6: a possible missing link for anti-inflammatory PPAR-delta signalling in pancreatic beta cells. Diabetologia 49: 2350–2358. 29. Zingarelli B, Piraino G, Hake PW, O’Connor M, Denenberg A, et al. (2010) Peroxisome proliferator-activated receptor {delta} regulates inflammation via NF-{kappa}B signaling in polymicrobial sepsis. Am J Pathol 177: 1834–1847. 30. Bishop-Bailey D, Bystrom J. (2009) Emerging roles of peroxisome proliferator- activated receptor-beta/delta in inflammation. Pharmacol Ther 124: 141–50. 31. Minamino T, Yoshida T, Tateno K, Miyauchi H, Zou Y, et al. (2003) Ras induces vascular smooth muscle cell senescence and inflammation in human atherosclerosis. Circulation. 108: 2264–2269. 32. Freund A, Orjalo AV, Desprez PY, Campisi (2010)J. Inflammatory networks during cellular senescence: causes and consequences. Trends Mol Med 16: 238– 46. Activated PPARd Protects from Senescence 33. Shelton DN, Chang E, Whittier PS, Choi D, Funk WD (1999) Microarray analysis of replicative senescence. Curr Biol 9: 939–945. 34. Kuilman T, Michaloglou C, Vredeveld LC, Douma S, van Doorn R, et al. Oncogene-induced senescence relayed by an interleukin-dependent inflamma- tory network. Cell 2008; 133: 1019–1031. 35. Brouilette SW, Moore JS, McMahon AD, Thompson JR, Ford I, et al. (2007): Telomere length, risk of coronary disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested casecontrolstudy. Lancet 369: 107– 114. 36. He T, Smith LA, Lu T, Joyner MJ, Katusic ZS (2011) Activation of peroxisome proliferator-activated receptor-{delta} enhances regenerative capacity of human endothelial progenitor cells by stimulating biosynthesis of tetrahydrobiopterin. Hypertension 58: 287–294. 37. Kim JY, Park HJ, Um SH, Sohn EH, Kim BO, et al. (2011) Sulforaphane suppresses vascular adhesion molecule-1 expression in TNF-a-stimulated mouse vascular smooth muscle cells: Involvement of the MAPK, NF-kB and AP-1 signaling pathways. Vascul Pharmacol. Dec 4 [Epub ahead of print]. 38. Thornton TM, Rincon M (2009) Non-Classical P38 Map Kinase Functions: Cell Cycle Checkpoints and Survival Int J Biol Sci 5: 44–52. 39. Wada T, Stepniak E, Hui L, Leibbrandt A, Katada T, et al. (2008) Antagonistic control of cell fates by JNK and p38-MAPK signaling. Cell Death Differ. 15: 89– 93. 40. Spallarossa P, Altieri P, Pronzato P, Aloi C, Ghigliotti G, et al. Sublethal doses of an anti-erbB2 antibody leads to death by apoptosis in cardiomyocytes sensitized by low prosenescent doses of epirubicin: the protective role of dexrazoxane. J Pharmacol Exp Ther. 2010 Jan;332(1) : 87–96. 41. Liang YJ, Chen CY, Juang SJ, Lai LP, Shyu KG, et al. (2010) Peroxisome proliferator-activated receptor delta agonists attenuated the C-reactive protein- induced pro-inflammation in cardiomyocytes and H9c2 cardiomyoblasts. Eur J Pharmacol 643: 84–92. 42. Yue TL, Nerurkar SS, Bao W, Jucker BM, Sarov-Blat L, et al. (2008) In vivo activation of peroxisome proliferator-activated receptor-delta protects the heart from ischemia/reperfusion injury in Zucker fatty rats. J Pharmacol Exp Ther 325: 466–474. 43. Kumagai T, Miki T, Kikuchi M, Fukuda T, Miyasaka N, et al. (1999) The proto-oncogene Bcl6 inhibits apoptotic cell death in differentiation-induced mouse myogenic cells. Oncogene 18: 467–475. 44. Baron BW, Anastasi J, Thirman MJ, Furukawa Y, Fears S, et al. (2002) The human programmed cell death-2 (PDCD2) gene is a target of BCL6 repression: implications for a role of BCL6 in the down-regulation of apoptosis. Proc Natl Acad Sci USA 99: 2860–2865. 45. Kojima S, Hatano M, Okada S, Fukuda T, Toyama Y, et al. (2001) Testicular germ cell apoptosis in Bcl6-deficient mice. Development 128: 57–65. 46. Gong J, Qian L, Kong X, Yang R, Zhou L, et al (2007) Cardiomyocyte apoptosis in the right auricle of patients with ostium secundum atrial septal defect diseases. Life Sci 80: 1143–1151. 47. Yamochi T, Kaneita Y, Akiyama T, Mori S, Moriyama M (1999) Adenovirus- mediated high expression of BCL-6 in CV-1 cells induces apoptotic cell death accompanied by down regulation of BCL-2 and BCL-X. Oncogene 18: 487– 494. 48. Albagli O, Lantoine D, Quief S, Quignon F, Englert C, et al. (1999) Overexpressed BCL6 (LAZ3) oncoprotein triggers apoptosis, delays S phase progression and associates with replication foci. Oncogene 18: 5063–5075. 49. Barnabe´ N, Zastre JA, Venkataram S, Hasinoff BB (2002) Deferiprone protects against doxorubicin-induced myocyte cytotoxicity. Free Radic Biol Med 33: 266–275. 50. Planavila A, Rodr´ıguez-Calvo R, Jove´ M, Michalik L, Wahli W, et al. (2005) Peroxisome proliferator-activated receptor beta/delta activation inhibits hyper- trophy in neonatal rat cardiomyocytes. Cardiovasc Res 65: 832–841. 51. Frias MA, Lang U, Gerber-Wicht C, James RW (2010) Native and reconstituted HDL protect cardiomyocytes from doxorubicin-induced apoptosis. Cardiovasc Res 85: 118–126. 52. Chen X, Wilson RM, Kubo H, Berretta RM, Harris DM, et al. (2007) Adolescent feline heart contains a population of small, proliferative ventricular myocytes with immature physiological properties. Circ Res 100: 536–544. 53. Konorev EA, Vanamala S, Kalyanaraman B (2008) Differences in doxorubicin- induced apoptotic signaling in adult and immature cardiomyocytes. Free Radic Biol Med 45: 1723–1728. 54. De Angelis A, Piegari E, Cappetta D, Marino L, Filippelli A, et al. (2010) Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function. Circulation 121: 276–292. 55. Antos CL, McKinsey TA, Dreitz M, Hollingsworth LM, Zhang CL, et al. (2003) Dose-dependent blockade to cardiomyocyte hypertrophy by histone deacetylase inhibitors. J Biol Chem 278: 28930–28937. 56. Stepp MA, Liu Y, Pal-Ghosh S, Jurjus RA, Tadvalkar G, et al. (2007) Reduced migration, altered matrix and enhanced TGF beta1 signaling are signatures of mouse keratinocytes lacking Sdc1. J Cell Sci 120: 2851–2863. 57. Ottonello L, Bertolotto M, Montecucco F, Bianchi G, Dallegri F (2009) Delayed apoptosis of human monocytes exposed to immune complexes is reversed by oxaprozin: role of the Akt/IkappaB kinase/nuclear factor kappaB pathway. Br J Pharmacol 157: 294–306. PLOS ONE | www.plosone.org 13 September 2012 | Volume 7 | Issue 9 | e46126